<?xml version="1.0" encoding="UTF-8" standalone="no"?>
<pubmed-document>
<record>
<header>
<identifier>23395225</identifier>
<setSpec>1885-1398</setSpec>
</header>
<metadata xmlns="http://example.org/myapp/" xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:dcterms="http://purl.org/dc/terms/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://example.org/myapp/schema.xsd">
<dc:author>Medrano Ramírez, Gabriel</dc:author>
<dc:author>Cardiel Ríos, Mario Humberto</dc:author>
<dc:author>Díaz Jouanen, Efraín</dc:author>
<dc:author>Espinosa Morales, Rolando</dc:author>
<dc:author>Fraga Mouret, Antonio</dc:author>
<dc:author>Barreira Mercado, Eduardo Rubén</dc:author>
<dc:author>Talavera Piña, Juan Osvaldo</dc:author>
<dc:author>Muñoz Barradas, Francisco José</dc:author>
<dc:author>Garza Elizondo, Mario Alberto</dc:author>
<dc:author>Vera Lastra, Olga Lidia</dc:author>
<dc:author>Díaz Borjón, Alejandro</dc:author>
<dc:author>Barile Fabris, Leonor Adriana</dc:author>
<dc:author>Arce Salinas, César Alejandro</dc:author>
<dc:author>Flores Murrieta, Francisco Javier</dc:author>
<dc:author>Esquivel Valerio, Jorge Antonio</dc:author>
<dc:author>Luján Estrada, Miguel</dc:author>
<dc:description xml:lang="en">Biotechnological drugs (BTDs) are complex molecules whose manufacturing process precludes the ability to identically reproduce the structure of the original product, and therefore there cannot be an absolute equivalence between the original (innovative) medication and its biosimilar counterpart. BTDs have been proven useful in the treatment of several rheumatic diseases, however their high cost has prevented their use in many patients. Several BTD patents have expired or are close to expire, triggering the development of structurally similar drugs with efficacy and safety profiles comparable to the innovative compound; however, these must be evaluated through evidence based medicine. The Mexican General Health Law contemplates the registry of these biosimilar drugs for their use in our country. This document is a forethought from members of the Mexican College of Rheumatology, pharmacologists, and epidemiologists, in accordance with Mexican health authorities regarding the necessary scientific evidence required to evaluate the efficacy and safety of biosimilar drugs before and after their arrival to the Mexican market.</dc:description>
<dc:type>Journal Article</dc:type>
<dc:language>es</dc:language>
<dc:date>2013 Mar-Apr </dc:date>
<dc:title xml:lang="en">Biosimilar drugs in Mexico: position of the Mexican College of Rheumatology, 2012.</dc:title>
<dc:publisher>Reumatologia clinica</dc:publisher>
</metadata>
</record>
</pubmed-document>
